BridgeBio reports Q4 net loss of $1.40/share; Attruby launch with 1,028 scripts, EU approval triggers $75M milestone

BridgeBio Pharma, Inc.

2024-FY EPS reported -$2.88 revenue$221,902,000

Attruby (acoramidis) prescriptions reached 1,028 from 516 prescribers as of Feb 17; EU approval on Feb 10 triggered $75M milestone.
Q4 2024 net loss $265.1M ($1.40 EPS); full-year net loss $535.8M ($2.88 EPS).
Q4 revenue $5.9M including $2.9M Attruby sales; full-year revenue $221.9M driven by $207.7M from Bayer/Kyowa Kirin deals.
Cash, cash equivalents and short-term restricted cash $681.2M at Dec 31, 2024, up from $392.6M at Dec 31, 2023.
Three Phase 3 trials (LGMD2I, ADH1, achondroplasia) fully enrolled; last participant last visit expected 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.